TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02201693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MODULEN IBD
Description: 2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MODULEN IBD
Description: 25% of daily caloric requirements, approx. 500mL/day
Study: NCT04325659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Bridge Device
Description: Inactive Bridge Device which is applied and looks identical to the active Bridge Device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Bridge Device
Description: Inactive Bridge Device which is applied and looks identical to the active Bridge Device
Study: NCT03915301

Intervention type: PROCEDURE
Intervention: Satisfaction assessed by the VAS [followed by its scale information in the Description]
Description: Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10

Intervention type: PROCEDURE
Intervention: Satisfaction assessed by the VAS [followed by its scale information in the Description]
Description: Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
Study: NCT03841227

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
Study: NCT01803451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin-(9-39)
Description: hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exendin -(9-39)
Description: 2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
Study: NCT03400891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program based on the theory of planned behaviour
Description: 14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
Study: NCT02529319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Ablation
Description: Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Ablation
Description: Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
Study: NCT01606449

Intervention type: PROCEDURE
Intervention: Surgical Therapy
Description: Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen.
Study: NCT04719247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Irreversibly damaged dental pulp is partially removed and a dressing either Turmeric or Thymus Vulgaris or Nigella Sativa or Aloe Vera is placed. Clinical and Radiographic signs and symptoms are assessed and compared with Formocresol.
Study: NCT01606449

Intervention type: PROCEDURE
Intervention: Surgical Therapy
Description: Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen.

Intervention type: PROCEDURE
Intervention: Surgical Therapy
Description: Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen.
Study: NCT02214498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril/hydrochlorothiazide
Description: The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enalapril/hydrochlorothiazide
Description: The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00606268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study: NCT01859702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution
Study: NCT03064633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone 8 mg
Description: At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine 80 µg
Description: At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 38 ml of the solution will be prepared to be used in transversus abdominis plane block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: 38 ml of the solution will be prepared to be used in transversus abdominis plane block
Study: NCT00878137

Intervention type: DEVICE
Intervention: INR by point-of-care instruments and venopuncture
Description: Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.

Intervention type: DEVICE
Intervention: INR by point-of-care instruments and venopuncture
Description: Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
Study: NCT02487173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respirio Flu Test
Description: The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Description: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofia® Influenza A+B Fluorescent Immunoassay (FIA)
Description: Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
Study: NCT06540378

Intervention type: DRUG
Intervention: Stiripentol
Study: NCT01005264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-removable fiberglass
Description: Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stabil-D®
Description: Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
Study: NCT04431531

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10 Sessions of yogatherapy associate with EMDR
Description: The first group will have Yogatherapy plus EMDR treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The second group will have EMDR without yogatherapy
Description: the second one will have EMDR treatment
Study: NCT01990898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
Study: NCT01362959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Description: The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cutaneous patch, containing no active substances
Description: During the study period of thirty (30) days, the control product will be applicated daily.
Study: NCT03636542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: Active comparator
Study: NCT04133519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 - Active behavioral Treatment Arm (Regulora; Gut-Directed Hypnotherapy Software as a Medical Device - SaMD)
Description: The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and comparator treatment arms receive a behavioral treatment, the subjects are blinded to active treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 2 - Active Comparator behavioral treatment arm (MR-1; Muscle Relaxation, Software as a Medical Device - SaMD)
Description: The comparator treatment consists of an identical treatment platform, scheduling platform, and reminder platform as the Active Treatment Arm, but in place of Gut-Directed Hypnotherapy there is a comparator relaxation treatment administered on an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
Study: NCT01283607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digicoach
Description: Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
Study: NCT02124746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Momelotinib tablets administered orally once daily
Study: NCT02195960

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intake anthocyanin-rich corn extract
Description: intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
Study: NCT00798824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling nasogastric tube placement
Description: The premature infant is fed with an indwelling nasogastric tube during feeding transition.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent orogastric tube placement
Description: The premature infant is fed with an intermittently placed orogastric tube during feeding transition.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube
Description: Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral gastric tube
Description: Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
Study: NCT02828748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention in patients treatment, only biopsy taken

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention in patients treatment, only biopsy taken
Study: NCT01369862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GHB16L2
Description: A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SPGNH buffer
Study: NCT00596765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological Cognitive Behavioral Therapy
Description: Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuropsychological Cognitive Behavioral Therapy
Description: Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
Study: NCT00443248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Heat Wash-Out Device
Description: No drug administered. Device tested twice with each subject.
Study: NCT02080026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Description: Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Controlled Human Malaria Infection
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Controlled Human Malaria Infection
Description: Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.

Intervention type: DRUG
Group type: OTHER
Intervention: chloroquine
Description: Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atovaquone/proguanil
Description: Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg

Intervention type: DRUG
Group type: OTHER
Intervention: atovaquone/proguanil
Description: Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg
Study: NCT05207696

Intervention type: OTHER
Intervention: retrospective data analysis
Description: The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)

Intervention type: OTHER
Intervention: retrospective data analysis
Description: The data of the patients who underwent papilla reconstruction surgery by one of the authors (S.O.B.) using semilunar incision with either PRF or CTG in the maxillary anterior teeth were included in the study. All selected patients had consent for using their data.The data of the patients included in the study were analyzed.(Baseline (BL) and follow-up (T1( first month) , T3 (third month), T6 (sixth month)) clinical data including periodontal evaluations (gingival index (GI), plaque index (PI), papillary bleeding index, pocket depth (PD), keratinized tissue width (KTW), gingival recession), papilla-associated recordings (alveolar crest-interdental contact point (AC-IC), alveolar crest-papilla tip (AC-PT), papilla tip-interdental contact point (PT-IC), papilla height loss (PHL), interdental tissue stroke (ITS) and papilla presence index (PPI)) and patient satisfaction were analyzed.)
Study: NCT04093622

Intervention type: GENETIC
Intervention: Genetically engineered NK cells
Description: No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT01118390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Nd:YAG 1064nm
Description: Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
Study: NCT04153370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: airtraq video laryngoscope was used for intubation of the infant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: glidescope
Description: glidescope video laryngoscope was used for intubation of the infant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: c-mac
Description: c-mac video laryngoscope was used for intubation of the infant
Study: NCT04172792

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high-caloric fatty diet
Description: see arm/group description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ultra-high-caloric fatty diet
Description: see arm/group description

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ultra-high-caloric carbohydrate-rich diet
Description: see arm/group description
Study: NCT03806829

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 250 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Wine
Description: 250 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea
Description: 250 ml

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange Juice
Description: 250 ml
Study: NCT03205995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721
Description: Intravenous loading dose followed by daily subcutaneous injections
Study: NCT00884429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy - Conventional
Description: Percussion Postural Drainage and thorax compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy - actual techniques
Description: Slow prolonged expiration and clearance rhinopharynx retrograde

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Airway suction
Description: Airway suction
Study: NCT01031147

Intervention type: OTHER
Intervention: Examination
Description: 3D-TOF-MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
Study: NCT01126983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture
Description: Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lead Anchor
Description: Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
Study: NCT03144557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD